A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.

tofacitinib ointment 20 mg/g

tofacitinib ointment 10 mg/g

placebo ointment (vehicle)

tofacitinib ointment 20 mg/g

tofacitinib ointment 10 mg/g

placebo ointment (vehicle)

Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12

Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8

Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12

Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8

Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12

Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8

Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)

Percent Change From Baseline to Week 8 in PASI

Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12

Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8

Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis

Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis

Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores

Change From Baseline to Week 8 in Clinic-Based ISI Scores

Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score

Change From Baseline to Week 8 in the DLQI Total Score

Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline

Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline